Aminoleban Infusion Soln Adverse Reactions

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

Reported incidence rates are based on data from 3324 patients with chronic liver disease, and a total of 35 patients (1.1%) experienced 52 adverse reactions (Drug Efficacy Reevaluation, March 1998, Japan).
Clinically significant adverse reactions: Hypoglycemia (frequency unknown): Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is recommended in such patients.
Hyperammonemia (frequency unknown): Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of Amino Acids (AMINOLEBAN), discontinue administration of nitrogen sources including Amino Acids (AMINOLEBAN) and institute appropriate measures.
Other adverse reactions: If adverse reactions are observed, discontinue the administration, and institute appropriate treatment. (See Table 3.)

Click on icon to see table/diagram/image

View ADR Monitoring Form

Aminoleban Infusion Soln Adverse Reactions

Manufacturer:

Otsuka (Philippines)

Distributor:

Zuellig